Evaluating medical device and material thrombosis under flow: current and emerging technologies
Access status:
Open Access
Type
ArticleAuthor/s
Hong, Jun KiGao, Lingzi
Singh, Jasneil
Goh, Tiffany
Ruhoff, Alexander
Neto, Chiara
Waterhouse, Anna
Abstract
Although blood-contacting medical devices are used widely, blood clot formation (thrombosis) leads to
device failure and potentially catastrophic adverse thrombotic events for patients, such as stroke or pulomonary
embolism. Systemic anti-thrombotic drugs aimed at reducing these ...
See moreAlthough blood-contacting medical devices are used widely, blood clot formation (thrombosis) leads to device failure and potentially catastrophic adverse thrombotic events for patients, such as stroke or pulomonary embolism. Systemic anti-thrombotic drugs aimed at reducing these complications do not always prevent device thrombosis and can cause increased bleeding risks. Therefore, our understanding of material thrombosis mechanisms needs to be improved in order to develop next generation blood-contacting medical devices and materials. Medical device development requires material thrombogenicity evaluation according to the International Standards 10993-4 Biological evaluation of medical devices– Selection of tests for interactions with blood, which highlights that one of the key aspects for testing is a clinically relevant flow system. In this review, we first provide an overview of the current knowledge regarding material thrombosis and important physical and biological aspects of blood flow in relation to thrombus formation. We then examine commonly used in vitro flow systems to evaluate material and medical device thrombosis, focusing on their capabilities, advantages and disadvantages. Finally, we explore recent advances in technology that will aid in improving the design and fabrication of flow systems, mechanistic analysis and computational modelling.
See less
See moreAlthough blood-contacting medical devices are used widely, blood clot formation (thrombosis) leads to device failure and potentially catastrophic adverse thrombotic events for patients, such as stroke or pulomonary embolism. Systemic anti-thrombotic drugs aimed at reducing these complications do not always prevent device thrombosis and can cause increased bleeding risks. Therefore, our understanding of material thrombosis mechanisms needs to be improved in order to develop next generation blood-contacting medical devices and materials. Medical device development requires material thrombogenicity evaluation according to the International Standards 10993-4 Biological evaluation of medical devices– Selection of tests for interactions with blood, which highlights that one of the key aspects for testing is a clinically relevant flow system. In this review, we first provide an overview of the current knowledge regarding material thrombosis and important physical and biological aspects of blood flow in relation to thrombus formation. We then examine commonly used in vitro flow systems to evaluate material and medical device thrombosis, focusing on their capabilities, advantages and disadvantages. Finally, we explore recent advances in technology that will aid in improving the design and fabrication of flow systems, mechanistic analysis and computational modelling.
See less
Date
2020Source title
Biomaterials ScienceVolume
8Issue
21Publisher
Royal Society of ChemistryLicence
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0Rights statement
Request permission from the publisher to reproduce material from this articleFaculty/School
Faculty of Science, School of ChemistryFaculty of Medicine and Health, School of Medical Sciences
The University of Sydney Multidisciplinary Centres and Institutes , Charles Perkins Centre
The University of Sydney Multidisciplinary Centres and Institutes , The University of Sydney Nano Institute
Faculty of Medicine and Health, Central Clinical School
Faculty of Engineering, School of Biomedical Engineering
Share